Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel Announces Receipt of Nasdaq Extension

04/11/16

BERKELEY HEIGHTS, N.J., April 11, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP); ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Announces Receipt of Nasdaq Extension 18.4 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results

03/24/16

-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT --

Read more

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 42.8 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results

03/17/16

BERKELEY HEIGHTS, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results 18.4 KB
Summary Toggle Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing

02/05/16

BERKELEY HEIGHTS, N.J., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market
Read more

Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing 17.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

02/02/16

BERKELEY HEIGHTS, N.J., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
Read more

Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference 17.9 KB
Summary Toggle Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016

01/11/16

Company to Present at the Biotech Showcase(TM) 2016 Conference

Read more

Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 28.7 KB
Summary Toggle Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium

12/14/15

Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium Berkeley Heights, NJ, December 14, 2015 - Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today
Read more

Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium 20.7 KB
Summary Toggle CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

11/23/15

In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting

Read more

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models 77.3 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

11/12/15

Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST

Read more

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results 39.9 KB
Summary Toggle Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference

11/09/15

CYC065 Predicted to be Effective in Leukemia and Triple Negative Breast Cancer

Read more

Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference 19.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results

11/05/15

BERKELEY HEIGHTS, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results 17.1 KB
Summary Toggle Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference

10/26/15

Mechanistic Rationale of CYC065 in Targeted Solid Tumors and Hematology

Read more

Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference 18.7 KB
Summary Toggle Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors

10/22/15

BERKELEY HEIGHTS, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
Read more

Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors 22.1 KB
Summary Toggle Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas

09/17/15

-Preclinical data presented at the SOHO 2015 meeting- -CYC065 cleared by FDA for first-in-human Phase 1 clinical trial- BERKELEY HEIGHTS, N.J., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the
Read more

Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas 20.1 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference

09/03/15

BERKELEY HEIGHTS, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference 15 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results

08/11/15

Conference Call Scheduled August 11, 2015 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results 35.3 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results

08/05/15

BERKELEY HEIGHTS, N.J., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results 18.3 KB
Summary Toggle First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder

07/02/15

- Unique Dual Action Through Inhibition of Cyclin E and ACTH Production in Pituitary Tumors -

Read more

First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder 22 KB
Summary Toggle Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis

06/29/15

Novel CDK Inhibitor-Based Approach to Treat Cystic Fibrosis

Read more

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis 23.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference

06/17/15

BERKELEY HEIGHTS, N.J., June 17, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference 15.2 KB

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter